H
Hengyou Weng
Researcher at Beckman Research Institute
Publications - 40
Citations - 6910
Hengyou Weng is an academic researcher from Beckman Research Institute. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 23, co-authored 36 publications receiving 3685 citations. Previous affiliations of Hengyou Weng include City of Hope National Medical Center & Guangzhou Institutes of Biomedicine and Health.
Papers
More filters
Journal ArticleDOI
Recognition of RNA N 6 -methyladenosine by IGF2BP proteins enhances mRNA stability and translation
Huilin Huang,Huilin Huang,Hengyou Weng,Hengyou Weng,Wen-Ju Sun,Xi Qin,Xi Qin,Hailing Shi,Hailing Shi,Huizhe Wu,Huizhe Wu,Huizhe Wu,Boxuan Simen Zhao,Boxuan Simen Zhao,Ana Mesquita,Chang Liu,Chang Liu,Celvie L. Yuan,Yueh-Chiang Hu,Stefan Hüttelmaier,Jennifer R. Skibbe,Rui Su,Rui Su,Xiaolan Deng,Xiaolan Deng,Xiaolan Deng,Lei Dong,Lei Dong,Miao Sun,Chenying Li,Chenying Li,Chenying Li,Sigrid Nachtergaele,Sigrid Nachtergaele,Yungui Wang,Yungui Wang,Chao Hu,Chao Hu,Kyle Ferchen,Kenneth D. Greis,Xi Jiang,Xi Jiang,Minjie Wei,Liang-Hu Qu,Jun-Lin Guan,Chuan He,Chuan He,Jian-Hua Yang,Jianjun Chen,Jianjun Chen +49 more
TL;DR: This work reports the insulin-like growth factor 2 mRNA-binding proteins as a distinct family of m6A readers that target thousands of mRNA transcripts through recognizing the consensus GG(m6A)C sequence, and identifies IGF2BPs as an additional class of N6-methyladenosine (m 6A) reader proteins.
Journal ArticleDOI
FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N 6-Methyladenosine RNA Demethylase
Zejuan Li,Hengyou Weng,Hengyou Weng,Rui Su,Xiaocheng Weng,Xiaocheng Weng,Zhixiang Zuo,Zhixiang Zuo,Zhixiang Zuo,Chenying Li,Chenying Li,Huilin Huang,Sigrid Nachtergaele,Lei Dong,Chao Hu,Chao Hu,Chao Hu,Xi Qin,Lichuan Tang,Yungui Wang,Yungui Wang,Yungui Wang,Gia-Ming Hong,Hao Huang,Xiao Wang,Ping Chen,Sandeep Gurbuxani,Stephen Arnovitz,Yuanyuan Li,Shenglai Li,Jennifer Strong,Mary Beth Neilly,Richard A. Larson,Xi Jiang,Xi Jiang,Pumin Zhang,Jie Jin,Chuan He,Jianjun Chen,Jianjun Chen +39 more
TL;DR: It is shown that FTO, as an m6A demethylase, plays a critical oncogenic role in acute myeloid leukemia (AML) and provides profound insights into leukemogenesis and drug response.
Journal ArticleDOI
R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling
Rui Su,Lei Dong,Chenying Li,Sigrid Nachtergaele,Mark Wunderlich,Ying Qing,Xiaolan Deng,Yungui Wang,Yungui Wang,Xiaocheng Weng,Chao Hu,Chao Hu,Mengxia Yu,Jennifer R. Skibbe,Qing Dai,Dongling Zou,Tong Wu,Kangkang Yu,Hengyou Weng,Huilin Huang,Kyle Ferchen,Xi Qin,Bin Zhang,Jun Qi,Atsuo T. Sasaki,David R. Plas,James E. Bradner,Minjie Wei,Guido Marcucci,Xi Jiang,James C. Mulloy,Jie Jin,Chuan He,Jianjun Chen,Jianjun Chen +34 more
TL;DR: While R-2HG accumulated in IDH1/2 mutant cancers contributes to cancer initiation, this work demonstrates anti-tumor effects of 2HG in inhibiting proliferation/survival of FTO-high cancer cells via targeting FTO/m6A/MYC/CEBPA signaling.
Journal ArticleDOI
METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification
Hengyou Weng,Huilin Huang,Huizhe Wu,Xi Qin,Boxuan Simen Zhao,Lei Dong,Hailing Shi,Jennifer R. Skibbe,Chao Shen,Chao Hu,Chao Hu,Yue Sheng,Yungui Wang,Yungui Wang,Mark Wunderlich,Bin Zhang,Louis C. Dore,Rui Su,Xiaolan Deng,Xiaolan Deng,Kyle Ferchen,Chenying Li,Chenying Li,Miao Sun,Zhike Lu,Xi Jiang,Guido Marcucci,James C. Mulloy,Jian-Hua Yang,Zhijian Qian,Minjie Wei,Chuan He,Jianjun Chen +32 more
TL;DR: The results reveal the SPI1-METTL14-MYB/MYC signaling axis in myelopoiesis and leukemogenesis and highlight the critical roles of METTL14 and m6A modification in normal and malignant hematopoiedis.
Journal ArticleDOI
m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer
TL;DR: The up-to-date knowledge of the pathological roles and underlying molecular mechanism of m6A modifications (in both coding and non-coding RNAs) in cancer pathogenesis and drug response/resistance are reviewed, and the therapeutic potential of targeting m 6A regulators for cancer therapy is discussed.